Blood Sugar News and Research

RSS

Blood sugar concentration, or glucose level, refers to the amount of glucose present in the blood of a human or animal. Normally, in mammals the blood glucose level is maintained at a reference range between about 3.6 and 5.8 mM (mmol/l). It is tightly regulated as a part of metabolic homeostasis.

High-fiber diet beats metformin for blood sugar and weight in trial

High-fiber diet improves blood sugar and weight more than metformin in a small diabetes trial.

7 Oct 2026

Innovative material uses visible light to disinfect chronic wounds

Chronic wounds place a burden on both patients and the healthcare system. Researchers at Empa are therefore working on an innovative material that releases active ingredients when exposed to visible light.

6 Oct 2026

Ultraprocessed meals produce distinct metabolic and brain responses

Most nutrition science suggests that meals with the same basic nutritional profile will have the same impact on a person's blood sugar.

5 Oct 2026

Gut mRNA tech supercharges vaccine and GLP-1 delivery

From vaccines to gene therapies, mRNA medicines often rely on tiny fat-based particles called lipid nanoparticles, or LNPs, to carry treatments where they need to go.

5 Oct 2026

Lab-grown human pituitary cells work and survive after transplantation into a primate

Researchers in Japan have transplanted pituitary tissue grown from human stem cells into a primate whose pituitary gland had been surgically removed, successfully restoring critical hormone signals.

1 Oct 2026

Very low carbohydrate diets show potential benefits in children with type 1 diabetes

Very low carbohydrate (VLC) diets may be associated with health benefits in children with type 1 diabetes (T1D) and were not associated with acute diabetes complications, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has found.

1 Oct 2026

CBL-514 injection reduces visceral and subcutaneous fat in trials

Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

1 Oct 2026

Mauritius becomes first country to reverse type 2 diabetes epidemic

New research to be presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that the small island nation of Mauritius is the first country in the world to prove it is reversing the type 2 diabetes epidemic using the objective gold standard testing method of the 2-hour oral glucose tolerance test (2 hour OGTT).

1 Oct 2026

Real-world data reveals higher reported GLP-1 side effects in female patients

The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health discusses the wide-ranging issues relating to use of GLP-1 RA drug use in women.

1 Oct 2026

GLP-1 receptor agonist exposure shows no link to major adverse pregnancy outcomes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health shows that, following a review and meta-analysis of available studies, use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) drugs for diabetes and weight management in women living with diabetes is not associated with adverse pregnancy outcomes in most cases.

1 Oct 2026

Early-onset type 2 diabetes trial demonstrates significant 24-week fat loss

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Regional Health Americas journal shows that in people who have developed early onset type 2 diabetes (EOT2D) (aged under 45 years), around half these T2D cases can be reversed with a low-energy diet combined with a structured exercise program.

1 Oct 2026

Study examines the real-world use of GLP-1 RA drugs in children and young people

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.

30 Sep 2026

$5.7 million NIH grant supports research on why lean people develop insulin resistance

A Wayne State University research team was awarded a $5.7 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health focused on discovering the biological mechanisms that may help explain why some lean people develop insulin resistance while some people with obesity remain sensitive to insulin.

29 Sep 2026

First EU Screening Week urges citizens to know their numbers

At a dedicated press conference at the EASD Annual Meeting in Milan, organized by the European Diabetes Forum (EUDF), three leading European cardiometabolic scientific associations - the European Society of Cardiology (ESC), the European Association for the Study of Diabetes (EASD) and the European Association for the Study of Obesity (EASO) - joined European Commissioner for Health and Animal Welfare Olivér Várhelyi to welcome the launch of the first-ever EU Screening Week.

29 Sep 2026

Greater variation in blood pressure associated with higher risk of death and strokes

Greater variation in blood pressure between research visits was associated with a higher risk of death in a study of more than 57,000 UK Biobank participants.

29 Sep 2026

Short voice recordings could screen patients for type 2 diabetes

Signs of type 2 diabetes can be detected in just a few seconds from the way someone talks, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows.

29 Sep 2026

Continuous glucose monitors show strong survival benefits for type 2 diabetes patients

People with type 2 diabetes (T2D) on basal insulin, starting continuous glucose monitoring (CGM) had a 44% lower risk of dying from any cause after one year compared with those who did not use CGM, with the risk being 35% lower after two years, according to an analysis of patient data being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

28 Sep 2026

Exam stress significantly raises blood sugar levels in medical students

Exam stress is associated with significant increases in blood sugar levels in medical students both during exams and the days leading up to them, according to new research being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

27 Sep 2026

New study tracks rising heart and kidney risks in people with type 2 diabetes

The risk of developing chronic kidney disease (CKD) or heart failure (HF), or dying, following a type 2 diabetes (T2D) diagnosis increases substantially over time, according to new research being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

27 Sep 2026

Gut bacteria signature may predict type 2 diabetes risk

Changes in the composition of bacteria in the gut could provide early warning of type 2 diabetes (T2D), new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has found.

27 Sep 2026